Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?

Eli Lilly and Company (NYSE:LLY) is one of the Stocks That Will Make You Rich Over the Next 3 Years. Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over the past 30 days, and the Street expects more than 13.6% upside from the current level.

Recently, on June 25, Leerink analyst David Risinger raised the firm’s price target on the stock from $1,119 to $1,232, while maintaining an Outperform rating on the shares. Earlier, on June 22, Berenberg analyst Kerry Holford also raised the firm’s price target on the stock to $1,135 from $1,050 and kept a Hold rating on the shares.

​The ratings have been based on several positive news reports over the past few weeks and strong demand for metabolic treatments Mounjaro and Zepbound. Recently, on June 24, Eli Lilly and Company (NYSE:LLY) announced completing the acquisition of Centessa Pharmaceuticals, which is a clinical-stage company focused on developing a new class of medicines for narcolepsy and other sleep-wake disorders. Following the release, the stock gained roughly 1.5%.

​Management noted that Centessa’s work centers on orexin receptor 2 agonists, which target the orexin system in the brain that controls wakefulness, alertness, and sleep stability. The company also emphasized the broader potential of the orexin system beyond narcolepsy, noting its relevance to a range of conditions linked to disrupted sleep. The acquisition signals Lilly’s strong push towards neuroscience and sleep medicine.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.